Engineering Chimeric Antigen Receptors For Durable Control Over Hiv-1 Replication

Loading...
Thumbnail Image
Degree type
Doctor of Philosophy (PhD)
Graduate group
Cell & Molecular Biology
Discipline
Subject
adoptive T cell therapy
chimeric antigen receptor
HIV-1
Allergy and Immunology
Immunology and Infectious Disease
Medical Immunology
Microbiology
Virology
Funder
Grant number
License
Copyright date
2018-02-23T20:17:00-08:00
Distributor
Related resources
Contributor
Abstract

This thesis project aimed to develop chimeric antigen receptors (CARs) capable of durably suppressing the Human Immunodeficiency Virus Type 1 (HIV) replication, by building upon a previous CD4-based CAR that was employed in several clinical trials. We applied lessons learned from cancer-targeting CARs to optimize the CAR vector backbone, promoter, HIV targeting moiety, and transmembrane and signaling domains, in an effort to determine which components augmented the ability of CD8 T cells to control HIV replication. CD8 T cells expressing the optimized CARs were at least 50-fold more potent in vitro at controlling HIV replication than the original CD4 CAR or TCR-based approaches and substantially better than broadly neutralizing antibody-based CARs. We then utilized a humanized mouse model of HIV infection to demonstrate superior control over HIV replication, better protection of CD4 T cells, and greater CAR T cell expansion with the optimized vectors compared to the original clinical trial vector. Compared to optimized CD4 CARs containing the CD28 costimulatory domain, CARs containing 4-1BB expanded better in vivo in the absence of antigen and resulted in greater control over HIV replication. We found that the CD4 CAR promoted infection of transduced CD8 T cells and employed CCR5 zinc finger nucleases (ZFNs) or a GP41-based fusion inhibitor to protect the CAR T cells. We employed ZFN-pretreated, CAR-transduced CD8 T cells in our mouse models and saw an enrichment of the disrupted alleles in HIV-infected mice compared to mock controls. In humans, a functional cure will require CAR T cells to prevent the spread of HIV following virus reactivation from the latent reservoir. We modeled this scenario in vitro using ART patient T cells and latency reversing agents (LRAs). Preliminary data suggest that CD4 CAR T cells can respond to low levels of antigen produced by resting ART patient cells in the presence of LRAs. Together, these data indicate that potent HIV-specific T cells can be generated using improved CAR design and provide optimism that CAR T cells could help achieve a functional cure.

Advisor
James L. Riley
Date of degree
2017-01-01
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation